Publication | Closed Access
A multicenter, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNF-α antibody afelimomab in patients with sepsis syndrome
57
Citations
0
References
2001
Year
InflammationDose-ranging Pharmacokinetic StudyImmunodeficienciesImmunologyTherapeutic EfficacySepsisImmune SurveillanceImmunosuppressionImmunotherapyMedicineSepsis SyndromeAnti-tnf-α Antibody Afelimomab
No additional data available for this publication yet. Check back later!